Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01022970 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 5
- Study locations
NCT01022970: Completed Phase 2 study of Eosinophilic Esophagitis, sponsored by Novartis Pharmaceuticals.
NCT01022970 is a Phase 2 study of Eosinophilic Esophagitis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 25 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01022970, a Phase 2 study of Eosinophilic Esophagitis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to investigate the effects of a 12 week course of intravenous QAX576 6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients by 75% or greater when compared with baseline.
Conditions Studied
Interventions
- DRUG QAX576 placebo
- DRUG QAX576
Study Locations (5)
California
- Stanford Medical Center and Lucile Packard Children's Hospital - Stanford
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Minnesota
- Mayo Clinic - Minneota
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Virginia
- Oral Alpan, 6210 Old Keene Mill Court, - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-11 |
| Phase | Phase 2 |
What the finished NCT01022970 record still lists
NCT01022970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which QAX576 placebo is the first listed.
NCT01022970 lists 5 locations in 5 states (California, Illinois, Minnesota).
Frequently Asked Questions
What is clinical trial NCT01022970 about?
NCT01022970 is a clinical study titled "Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis". This study is designed to investigate the effects of a 12 week course of intravenous QAX576 6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients by 75% or greater when compared with baseline.
What is the current status of trial NCT01022970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2009-11.
What conditions does trial NCT01022970 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT01022970?
The interventions under investigation include: QAX576 placebo (DRUG), QAX576 (DRUG).
Who is sponsoring clinical trial NCT01022970?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01022970 being conducted?
This trial has 5 study locations across California, Illinois, Minnesota, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01022970's enrollment target sits among peer trials
25 34th of 44 higher than 11 of 44 other Eosinophilic Esophagitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia